Jim Cramer Discusses These 10 Stocks & Comments On OpenAI’s Valuation

6. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders In Q3 2024: 106

Eli Lilly and Company (NYSE:LLY) is one of the most commonly discussed stocks on Cramer’s morning show. He interviewed the firm’s CEO David Ricks at the JPMorgan Healthcare Conference, and despite tepid financial performance, remains a fan of the stock. Cramer believes that not only are Eli Lilly and Company (NYSE:LLY)’s weight loss drugs better than rival Novo’s, but that the firm’s narrative in 2025 will also be shaped by drugs under development. His latest remarks also reflected this theme:

“One of the reasons you back out the dollar and you suddenly see some growth, uh, look I’m surprised that with the Mondelez, with some of these we stopped talking about GLP-1, and yet, Lilly’s doing quite well. The stock has been going up. I think there’s a bunch of new use cases coming up and there’s more, well it’s down today, but there’s more Mounjaro in the system. So you don’t just get directed to Wegovy by the doctors.”

“Well there’s so many, when I spoke with David Ricks whose the CEO, the number of trials going on, is shocking because it just seems to do so many different things that are good. I think that the pre-diabetes and pre-Alzheimer’s are going, the two I’m focused on now. I was focused on the heavy drinking one. People don’t talk about that but after we saw what the previous President’s Surgeon General was saying, which was the skull and crossbones on liquor, I mean heavy drinking’s going to be something you better get it under control. Look I’m waiting for the Humana’s of the world to say look if you drink heavily we’re not going to cover you.”